McKesson (NYSE:MCK) Stock Gets Price Target Boost from TD Cowen

McKesson (NYSE:MCK) had its price target upped by analysts at TD Cowen from $1,006.00 to $1,200.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen‘s target price indicates a potential upside of 11.62% from the company’s previous close.

A number of other research firms have also recently issued reports on MCK. Citigroup boosted their price objective on shares of McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Leerink Partners increased their target price on shares of McKesson from $1,070.00 to $1,200.00 and gave the stock an “outperform” rating in a report on Thursday. Wells Fargo & Company raised their target price on McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 11th. Bank of America boosted their price target on McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Finally, Robert W. Baird set a $1,015.00 price target on McKesson in a research report on Thursday, August 6th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,023.24.

McKesson Price Performance

McKesson stock traded up $5.62 during trading hours on Thursday, reaching $1,075.06. The company had a trading volume of 886,800 shares, compared to its average volume of 918,122. McKesson has a 12-month low of $723.68 and a 12-month high of $1,121.50. The company has a 50-day moving average price of $931.17 and a 200 day moving average price of $865.74. The firm has a market cap of $125.34 billion, a price-to-earnings ratio of 28.84, a P/E/G ratio of 1.99 and a beta of 0.27.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. The company had revenue of $110.96 billion during the quarter, compared to analyst estimates of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business posted $9.86 EPS. As a group, research analysts expect that McKesson will post 44.71 earnings per share for the current year.

Insider Buying and Selling

In other McKesson news, Director Bradley Lerman sold 301 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Francisco Fraga sold 600 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $1,050.00, for a total value of $630,000.00. Following the completion of the transaction, the executive vice president owned 5,064 shares of the company’s stock, valued at approximately $5,317,200. This trade represents a 10.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,812 shares of company stock valued at $1,794,182 over the last ninety days. Company insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. DSG Capital Advisors LLC lifted its holdings in shares of McKesson by 20.0% during the third quarter. DSG Capital Advisors LLC now owns 4,134 shares of the company’s stock valued at $3,530,000 after purchasing an additional 690 shares during the last quarter. Northbridge Financial Group LLC boosted its position in shares of McKesson by 2.1% in the 3rd quarter. Northbridge Financial Group LLC now owns 766 shares of the company’s stock worth $706,000 after purchasing an additional 16 shares in the last quarter. AMG National Trust Bank grew its stake in shares of McKesson by 2.0% in the 3rd quarter. AMG National Trust Bank now owns 3,596 shares of the company’s stock worth $3,071,000 after buying an additional 69 shares during the last quarter. Keybank National Association OH grew its stake in shares of McKesson by 4.5% in the 3rd quarter. Keybank National Association OH now owns 4,460 shares of the company’s stock worth $3,808,000 after buying an additional 192 shares during the last quarter. Finally, Cornerstone Wealth Management LLC purchased a new stake in shares of McKesson in the 3rd quarter worth approximately $256,000. 85.07% of the stock is currently owned by institutional investors.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Fiscal Q2 2027 adjusted earnings were $11.68 per share, ahead of analyst expectations, while revenue reached about $111 billion, also beating estimates and rising roughly 7.5% year over year. Q2 results and guidance
• Positive Sentiment: McKesson raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40. Management cited specialty-drug and GLP-1 distribution demand, higher prescription volumes, and operating gains as growth drivers. Earnings call highlights
• Positive Sentiment: Several analysts lifted price targets to $1,200, including Leerink Partners, TD Cowen and Evercore ISI, signaling confidence in the outlook. Leerink Partners rating TD Cowen target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The stated purpose and planned nature of the sale may lessen its significance as a signal about his view of the company. SEC filing
• Negative Sentiment: RBC raised its target to $965 but kept a “sector perform” rating; that target remains below the share price cited in the report, reflecting a more cautious view of near-term upside. RBC rating

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.